Trenbolone

As an important branch of androgen and anabolic steroid drugs, trenbolone exerts a significant protein anabolic effect by binding to the androgen receptor with high affinity. Its protein synthesis-promoting activity far exceeds that of testosterone, and its androgenic activity is relatively controllable. In clinical scenarios, this drug is mainly used for the treatment of chronic wasting diseases, osteoporosis, severe trauma, postoperative recovery and other conditions, helping patients increase muscle mass and improve the body's nutritional status. It is especially suitable for adult patients with long-term insufficient nutritional intake and declined tissue repair ability, and has clear application value in the fields of sports medicine, geriatric disease treatment, etc.

The global market size of trenbolone-related preparations is approximately USD 320 million, with an average annual compound growth rate of around 4.7% in the past three years. The growth momentum mainly comes from the rising demand for the treatment of sarcopenia in the elderly and the expansion of medication in the veterinary field. In terms of the competitive landscape, European and American enterprises occupy a dominant position in the original research and high-end generic drug markets, while domestic enterprises, relying on their cost advantages, have become the core suppliers of trenbolone API in the world. At present, domestic API production capacity accounts for more than 60% of the global total production capacity. There are 7 domestic manufacturers that have obtained US FDA certification and EU CEP certification, and their products are mainly exported to North America, Europe and Southeast Asian markets.

The original research enterprise of trenbolone is Servier from France, with the original brand name "Parabolan". Its core compound patent expired globally in 1997. The main dosage form approved for the original product is injection, with a specification of 76mg/1mL. It has been included in the FDA Reference Listed Drug Catalog, but has not yet been included in China's *Catalog of Reference Preparations for Chemical Drugs*. In China, there are currently 11 trenbolone API registration numbers, among which 6 have obtained A status through associated review with preparations, and another 3 enterprises have obtained marketing approval for trenbolone injection. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of trenbolone impurity reference standards. Most products are available from stock. For in-stock orders placed before 16:00, delivery can be made on the same day. All products meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for the quality research and registration declaration links of API and preparation enterprises.